Alemtuzumab (MabCampath)

DRUG2 trials

Sponsors

Goethe University, Genzyme, a Sanofi Company

Conditions

Adult Acute Lymphocytic Leukemia T-cellChronic Lymphocytic LeukemiaLymphoma, Lymphoblastic

Phase 2

Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath

CompletedNCT00199030

Goethe UniversityAdult Acute Lymphocytic Leukemia T-cell, Lymphoma, Lymphoblastic

Start: 2004-02-29End: 2008-04-30Updated: 2023-03-20

Unknown Phase

Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia

TerminatedNCT00836043

Genzyme, a Sanofi CompanyChronic Lymphocytic Leukemia

Start: 2008-10-31End: 2009-04-30Updated: 2013-12-03